The dopaminergic nigrostriatal system in sleep deprivation in cats

Oganesyan, G. A.; Aristakesyan, E. A.; Романова, И. В.; Belova, V. A.; Artamokhina, I. V.

doi:10.1007/s11055-008-9047-9

Cited by 6 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sleep deprivation was accompanied by decrease of D1 dopamine receptor immunoreactivity and increase of D2 dopamine receptor immunoreactivity in the caudate nucleus [ 31 ]. D1 dopamine receptor level was decreased, in contrast, D2 dopamine receptor level was not changed, and D3 dopamine receptor level was increased in the striatum of mice by sleep deprivation.…”

Section: Discussionmentioning

confidence: 99%

Dexmedetomidine Ameliorates Sleep Deprivation-Induced Depressive Behaviors in Mice

Moon

Kim

et al. 2018

Int Neurourol J

View full text Add to dashboard Cite

PurposeSleep deprivation induces depressive symptoms. Dexmedetomidine is a α2-adrenoreceptor agonist and this drug possesses sedative, anxiolytic, analgesic, and anesthetic-sparing effect. In this study, the action of dexmedetomidine on sleep deprivation-induced depressive behaviors was investigated using mice.MethodsFor the inducing of sleep deprivation, the mice were placed inside a water cage containing 15 platforms and filled with water up to 1 cm below the platform surface for 7 days. One day after sleep deprivation, dexmedetomidine at the respective dosage (0.5, 1, and 2 μg/kg) was intraperitoneally treated into the mice, one time per a day during 6 days. Then, forced swimming test and tail suspension test were conducted. Immunohistochemistry for tyrosine hydroxylase (TH), 5-hydroxytryptamine (5-HT; serotonin), tryptophan hydroxylase (TPH) and western blot for D1 dopamine receptor were also performed.ResultsSleep deprivation increased the immobility latency in the forced swimming test and tail suspension test. The expressions of TPH, 5-HT, and D1 dopamine receptor were decreased, whereas, TH expression was increased by sleep deprivation. Dexmedetomidine decreased the immobility latency and increased the expressions of TPH, 5-HT, and D1 dopamine receptor, whereas, HT expression was decreased by dexmedetomidine treatment.ConclusionsIn our results, dexmedetomidine alleviated sleep deprivation-induced depressive behaviors by increasing 5-HT synthesis and by decreasing dopamine production with up-regulation of D1 dopamine receptor.

show abstract

Section: Discussionmentioning

confidence: 99%

Dexmedetomidine Ameliorates Sleep Deprivation-Induced Depressive Behaviors in Mice

Moon

Kim

et al. 2018

Int Neurourol J

View full text Add to dashboard Cite

show abstract

“…Although not systematically studied, many psychiatrists use small doses of olanzapine or quetiapine (rather than drugs that act on benzodiazepine receptors). Such practice is indirectly supported by human and animal studies indicating that sleep loss results in excessive activation of dopaminergic systems in the brain (Oganesyam et al 2010;Volkow et al 2008). …”

Section: Circadian Rhythm Patternmentioning

confidence: 98%

Pharmacological Treatments for Bipolar Disorder: Present Recommendations and Future Prospects

Bowden¹

2010

Behavioral Neurobiology of Bipolar Disorder and Its Treatment

View full text Add to dashboard Cite

In selecting and adapting medications to treat the specific clinical features of a patient with bipolar disorder (BPD) over time, a foundation strategy is to have good working knowledge of up-to-date practice guidelines. The World Federation of Societies of Biological Psychiatry Guidelines has the reasoned advantage of weighing safety/tolerability as high as efficacy. Most successful treatments for BPD start to separate from placebo within 1 week; most differences between regimens occur within the first 4 weeks. This observation extrapolates to a strategy of discontinuing or adding a second drug for symptoms unimproved within 1 month of treatment initiation. The weight of evidence argues against starting treatment with combination regimens, despite evidence that over time most patients do receive combination drug regimens and appear to tolerate them well. The current design paradigm for adjunctive trials generally strongly weights trials in favor of the sponsor drug.Well managed, BPD is often compatible with fully good health, both symptomatically and functionally. Consequently, for whatever regimens are found to accomplish excellent symptom control, it is important to achieve regimens that are well tolerated by all bodily systems. This chapter emphasizes the tactics needed to accomplish this specific to individual medications. The chapter also addresses the serious, broad failure of pharmaceutical companies to develop new drugs with novel mechanisms for BPD therapy and proposes a series of steps that might reenergize drug development to the benefit of psychiatrists and patients alike.

show abstract

“…The stages of specimen processing for immunohistochemical studies were as described previously [3][4][5]. Experiments were performed on free-floating frontal brain sections of thickness 20 μm cut with a cryostat.…”

mentioning

confidence: 99%

The Role of AGRP in Regulating Dopaminergic Neurons in the Brain

Mikhrina

Романова

2015

Neurosci Behav Physi

Self Cite

View full text Add to dashboard Cite

A new protein found in rodent brains has extensive structural similarity with agouti protein, which is expressed in the skin and produces a rusty coloration of the coat in rodents [16]. Because of this, the new protein was named agouti-related protein (AGRP). AGRP mRNA has been shown to be present only in neurons in the arcuate (or infundibular) nucleus of the hypothalamus in various mammals [7,12]. This encodes a propeptide from which a convertasedependent process forms several active protein fragments [11,19].AGRP in the brain has been shown to be an endogenous antagonist of melanocortin receptors types 3 and 4, and its functional significance is assessed in the literature as being related to the control of feeding behavior as an appetite-activating factor [10,11, 23]. However, increases in appetite are not always associated with increases in the AGRP balance in the brain. Thus, for example, obesity developing as a result of increased food intake is accompanied by a decrease in AGRP expression [1, 10], which does not correspond to its functional role as an appetite activator. In addition, the literature contains reports of studies demonstrating the role of AGRP as a melanocortin receptor agonist [22], as well as the suggestion that it acts via other, as yet unknown, types of receptor [20], which widens our understanding of the functional significance of this peptide.Immunohistochemical studies have demonstrated the presence of AGRP-immunoreactive processes in various parts of the brain [7, 13], which seems to provide evidence of the involvement of this peptide in regulating a variety of body functions.Analysis of published data, along with our own observations, provides evidence that AGRP-immunoreactive processes are detected in those areas of the brain containing dopaminergic neurons themselves (the arcuate nucleus of the hypothalamus, the zona incerta, the ventral tegmental area, the paraventricular nucleus of the hypothalamus, the periacqueductal gray matter) and their targets (the preoptic area, the paraventricular and supraoptic nuclei of the hypothalamus, etc.) [7]. However, the literature lacks any data on the possible involvement of AGRP in regulating the functional activity of dopaminergic brain neurons. Thus, the aim of the present work was to determine the possibility and nature of the influences of AGRP on dopaminergic brain neurons. We performed immunohistochemical studies to support the existence of structural interactions of AGRPand dopaminergic neurons, as well as in vitro experiments in which living slices of brain areas containing dopaminerImmunoreactive processes containing agouti-regulated protein (AGRP) were detected in various dopaminergic structures in the brains of rats and mice. Double immunolabeling demonstrated the presence of AGRP-immunoreactive processes around the bodies of dopaminergic neurons. In in vitro experiments, incubation of brain tissue from the ventral tegmental area and hypothalamus with AGRP(83-132) identified significant reductions in the optical density of tyrosine h...

show abstract

The dopaminergic nigrostriatal system in sleep deprivation in cats

Cited by 6 publications

References 16 publications

Dexmedetomidine Ameliorates Sleep Deprivation-Induced Depressive Behaviors in Mice

Dexmedetomidine Ameliorates Sleep Deprivation-Induced Depressive Behaviors in Mice

Pharmacological Treatments for Bipolar Disorder: Present Recommendations and Future Prospects

The Role of AGRP in Regulating Dopaminergic Neurons in the Brain

Contact Info

Product

Resources

About